Barbara Parodi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6595644/publications.pdf

Version: 2024-02-01

759233 552781 34 704 12 26 citations h-index g-index papers 35 35 35 1152 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Short tandem repeat profiling for the authentication of cancer stemâ€like cells. International Journal of Cancer, 2021, 148, 1489-1498.	5.1	13
2	Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 233-246.	2.8	67
3	Biobanking and biomolecular resource research infrastructure: The Italian node. Biomedical Science and Engineering, 2020, , .	0.0	0
4	Extending the Minimum Information About Blobank Data Sharing Terminology to Describe Samples, Sample Donors, and Events. Biopreservation and Biobanking, 2020, 18, 155-164.	1.0	25
5	Cell Lines as Biological Models: Practical Steps for More Reliable Research. Chemical Research in Toxicology, 2019, 32, 1733-1736.	3.3	10
6	Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking. Biopreservation and Biobanking, 2017, 15, 270-276.	1.0	26
7	Towards new tools for bioresource use andÂsharing. Information Services and Use, 2017, 36, 133-146.	0.2	6
8	Biobanks: A Definition. The International Library of Ethics, Law and Technology, 2015, , 15-19.	0.4	24
9	Interlab Cell Line Collection: Bioresource of Established Human and Animal Cell Lines. Open Journal of Bioresources, 2015, 2, .	1.5	2
10	Public Biobanks: Calculation and Recovery of Costs. Science Translational Medicine, 2014, 6, 261fs45.	12.4	47
11	The Research Biobank of the Year Competition of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB): Aims and Achievements. Biopreservation and Biobanking, 2014, 12, 154-160.	1.0	2
12	Measuring the Contribution of Tumor Biobanks to Research in Oncology: Surrogate Indicators and Bibliographic Output. Biopreservation and Biobanking, 2013, 11, 235-244.	1.0	29
13	CREST biorepository for translational studies on malignant mesothelioma, lung cancer and other respiratory tract diseases: Informatics infrastructure and standardized annotation. Experimental and Therapeutic Medicine, 2012, 3, 540-546.	1.8	2
14	The role of a bioresource research impact factor as an incentive to share human bioresources. Nature Genetics, 2011, 43, 503-504.	21.4	66
15	Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Research, 2009, 37, D925-D932.	14.5	122
16	Correction: Article on the CREST Biorepository on Respiratory Tract Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1331-1331.	2.5	0
17	The CREST Biorepository: A Tool for Molecular Epidemiology and Translational Studies on Malignant Mesothelioma, Lung Cancer, and Other Respiratory Tract Diseases. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3013-3019.	2.5	21
18	Inhibition of Cell Growth, Induction of Apoptosis and Mechanism of Action of the Novel Platinum Compound cis-Diaminechloro-[2-(Diethylamino) Ethyl 4-Amino-Benzoate, N4]-Chloride Platinum (II) Monohydrochloride Monohydrate. Investigational New Drugs, 2004, 22, 3-16.	2.6	12

#	Article	IF	CITATIONS
19	Interoperability of CABRI Services and Biochemical Pathways Databases. Comparative and Functional Genomics, 2004, 5, 169-172.	2.0	5
20	Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice. Archives of Toxicology, 2003, 77, 584-590.	4.2	14
21	Preclinical in vitro evaluation of hematotoxicity of the cisplatin–procaine complex DPR. Anti-Cancer Drugs, 2003, 14, 163-166.	1.4	10
22	Species Identification and Confirmation of Human and Animal Cell Lines: A PCR-Based Method. BioTechniques, 2002, 32, 432-440.	1.8	82
23	Cisplatin combined with the new cisplatin-procaine complex dpr: In vitro and in vivo studies. European Journal of Cancer, 1996, 32, 2327-2333.	2.8	8
24	Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II). Cancer Chemotherapy and Pharmacology, 1995, 35, 371-376.	2.3	12
25	Molecular Probe Data Base (MPDB). Nucleic Acids Research, 1994, 22, 3474-3480.	14.5	3
26	The cell line data base and the new catalogue: Detailed information on 2650 human and animal cell lines. Cytotechnology, 1993, 11, S130-S133.	1.6	4
27	Molecular Probe Data Base: a database on synthetic oligonucleotides. Nucleic Acids Research, 1993, 21, 3007-3009.	14.5	7
28	Molecular Probe Database: a database on synthetic oligonucleotides. Nucleic Acids Research, 1992, 20, 2009-2011.	14.5	6
29	Analysis and comparison of information and data recorded in carcinogenicity and genotoxicity databases Environmental Health Perspectives, 1991, 96, 113-120.	6.0	2
30	Analysis and Comparison of Information and Data Recorded in Carcinogenicity and Genotoxicity Databases. Environmental Health Perspectives, 1991, 96, 113.	6.0	0
31	Polymorphism of the HLA-DPÎ 2 region detected by southern blot hybridization. Human Immunology, 1990, 27, 348-359.	2.4	1
32	Detection of HLA-DP serological allodeterminants by the use of radioiodinated DP molecules. European Journal of Immunology, 1987, 17, 743-750.	2.9	11
33	The same human alloreactive T cell clone can help both B lymphocytes and specific cytotoxic precursors Journal of Experimental Medicine, 1984, 159, 318-323.	8.5	7
34	Activation of human B lymphocytes: frequency of antigen-specific B cells triggered by alloreactive or by antigen-specific T cell clones. European Journal of Immunology, 1983, 13, 733-738.	2.9	57